Momentum handoff to a young engine
Hit Rate
2.4%
rare by design
NO
on the Q3 2018 call
2018-10-30
B+
The model's full reasoning — Q3 2018 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management describe a newer offering already producing real revenue that is growing much faster than the rest of the company, and treat it as the main driver of the company's future? From the transcript, there are several newer products mentioned: Prolia, Repatha, Aimovig, biosimilars, etc. But the question specifically asks about a "newer offering already producing real revenue that is growing much faster than the rest of the company" and treated as the main driver of the company's future. Looking at the transcript, management discusses many products. However, the question is likely referring to a specific one. The transcript mentions Aimovig as a strong launch, but it's still early. Prolia is growing 15% with 16% volume growth. Repatha growing 35%. But the question asks about "the main driver of the company's future." In the transcript, Bob Bradway says: "We believe biosimilars can be an important growth driver for us as well as we’re now launching KANJINTI, a biosimilar Herceptin and AMGEVITA, a biosimilar to Humira internationally." But that's not yet producing real revenue? Actually they have launched, so it is producing revenue. But is it growing much faster? They don't give numbers. Alternatively, the question might be about a specific product that is already producing revenue and growing fast. The transcript mentions "new and recently launched products had double-digit unit volume growth." But the question asks for a single offering. Perhaps the answer is NO because management does not single out one offering as the main driver; they have a portfolio. Or maybe they do treat Aimovig as a major driver? But Aimovig is very new, but they say it's off to a strong start. However, they don't say it's the main driver of the future. Looking at the overall tone, they emphasize innovation and pipeline. They mention seven new programs. But the question is about a "newer offering already producing real revenue" that is growing much faster than the rest. That could be Prolia or Repatha. But they don't explicitly say it's the main driver. I think the answer is NO because they don't describe a single offering as the main driver; they have multiple growth drivers. Thus, answer: NO.
← Back to the full AMGN analysis
Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript: does management describe a newer offering already producing real revenue that is growing much faster than the rest of the company, and treat it as the main driver of the company's future? Answer only YES or NO.
Companies that answered YES
| Ticker | Company | Call | Date | Call grade |
|---|
| NOAH |
Noah Holdings Limited |
Q1 2024 |
2024-05-30 |
D |
| DUOT |
Duos Technologies Group, Inc. |
Q4 2023 |
2024-04-01 |
F |
| HUYA |
HUYA Inc. |
Q4 2023 |
2024-03-19 |
C |
| ANGO |
AngioDynamics, Inc. |
Q1 2024 |
2023-10-04 |
B |
| CTHR |
Charles & Colvard, Ltd. |
Q1 2023 |
2022-11-06 |
F |
| YMM |
Full Truck Alliance Co. Ltd. |
Q2 2022 |
2022-08-25 |
C+ |
| ZH |
Zhihu Inc. |
Q3 2021 |
2021-11-22 |
D |
| UFI |
Unifi, Inc. |
Q4 2021 |
2021-08-07 |
B |
| FOSL |
Fossil Group, Inc. |
Q1 2018 |
2018-05-08 |
C |
| ATI |
Allegheny Technologies Incorporated |
Q1 2018 |
2018-04-24 |
B |
| FI |
Fiserv, Inc. |
Q4 2017 |
2018-02-27 |
C |
| MITK |
Mitek Systems, Inc. |
Q4 2017 |
2017-11-07 |
C+ |
How the model reasoned
CTHR · Q1 2023 → YESThe question is: "Using ONLY the supplied earnings call transcript: does management describe a newer offering already producing real revenue that is growing much faster than the rest of the company, a...YES The transcript shows Caydia lab-grown diamond revenues on charlesandcolvard.com up 85% YoY (while overall revenue fell 28% and moissanite sales fell 12%), and management positions the lab-grown diamond category as a key growth driver and long-term strategic focus. They describe it as "one of the hottest growing categories" with potential to exceed $8 billion, and state they will "definitely continue to grow the Diamond opportunity" while maintaining moissanite as core. They also highlight new collections and the "made not mined" campaign as central to future positioning.
FOSL · Q1 2018 → YESThe question is: "Using ONLY the supplied earnings call transcript: does management describe a newer offering already producing real revenue that is growing much faster than the rest of the company, a...YES The transcript describes the connected/smartwatch/wearables category as a newer offering already generating real revenue ($80 million, up 97% YoY) that is growing much faster than the rest of the business (overall sales down 2% reported / 7% constant currency; traditional watches down 6%). Management repeatedly positions it as a key driver of future growth, noting it is already nearly 20% of watch sales (up from 8%), improving overall watch growth by 900 bps, and that new product launches plus licensing (e.g., PUMA) will expand its role.
DUOT · Q4 2023 → YESThe question is: "Using ONLY the supplied earnings call transcript: does management describe a newer offering already producing real revenue that is growing much faster than the rest of the company, a...YES The transcript explicitly describes the newer AI services and data subscription offerings as already generating real recurring revenue (up 23% YoY while total revenue fell 50%), positions them as the key growth driver, and frames the shift to this subscription model as the critical priority for the next 12 months.
More from the question bank
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.